Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

157. PBMC levels of TFV-PP remained detectable for six days after the single 400 mg dose of CMX157, suggesting the possibility of a convenient, once-weekly dosing regimen.

CMX157 In Vitro Activity

The in vitro antiviral activity of CMX157 was evaluated in PBMCs for wild-type and nucleotide reverse transcriptase inhibitors (NRTI)-resistant HIV strains.  CMX157 was effective and highly potent against all clinically-important HIV strains, including drug resistant isolates that are known to be unresponsive to tenofovir.  CMX157 was observed to have highly potent antiviral activity against XMRV in vitro, with an EC50 approximately 20-fold more potent than the anti-retroviral drug azidothymidine (AZT) and 800-fold more potent than tenofovir.  Data were also presented that showed CMX157 is not a substrate in vitro for human Organic Anion Transporter 1 (hOAT1), which actively transports tenofovir into renal proximal tubule cells of the kidney and is linked to tenofovir-induced nephrotoxicity.  Consequently, CMX157 has significantly reduced potential to cause nephrotoxicity.

CMX157 findings were featured in an oral presentation, CMX157 (Hexadecyloxypropyl Tenofovir), a Clinical Stage Antiretroviral with In Vitro Activity against HIV and XMRV, by Randall Lanier, Ph.D., Senior Director of Virology of Chimerix, at the HIV DART 2010 Frontiers in Drug Development for Antiretroviral Therapies conference.  A copy of Dr. Lanier's oral presentation and poster are available on the Chimerix website at www.chimerix.com.  

About CMX157

CMX157 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to chemically modify tenofovir, marketed as the prodrug Viread, an antiviral agent approved for the treatment of HIV and chronic hepatitis B. Chimerix's propr
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 DURECT Corporation (Nasdaq: ... a multi-dose Phase 1 clinical trial of an ... DURECT,s Epigenomic Regulator Program.  DUR-928 is an endogenous, ... broad applicability in metabolic diseases such as nonalcoholic ...  It may also play an important role in ...
(Date:3/30/2015)... , March 30, 2015   GlassesUSA , the ... closing of $12.5 million in new financing led by ... The funding will further GlassesUSA,s aggressive business growth and accelerate ... market of online eyewear, both B2C and B2B. ... , COO Eldad Rothman , and CTO Roy ...
(Date:3/30/2015)... 2015  Zimmer Holdings, Inc. (NYSE and SIX: ... ("EC") has conditionally cleared Zimmer,s proposed acquisition of ... upon Zimmer entering into agreements with a suitable ... package previously submitted to the EC.  Zimmer expects ... term.  As previously announced, the proposed transaction also ...
Breaking Medicine Technology:DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 2Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 3Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 4Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger 5
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... has been filed in California Superior Court on ... a serious heart birth defect after his mother was ... pregnancy. According to the March 6th filing in Alameda ... to alleviate nausea and vomiting that she experienced in ...
(Date:3/30/2015)... 2015 On March 11, 2015, Elle Magazine, ... Fat,” details six new treatment options for dealing with stubborn, ... is a topical product. The other three technologies use devices ... ) or freezing cold ( CoolSculpting ) to kill fat ... available to us to permanently remove unwanted fat," says Dr. ...
(Date:3/30/2015)... USA (PRWEB) March 30, 2015 In ... on March 17th, Governor Chris Christie is championing effective ... use disorders.New Jersey is scrambling to recover funds to ... the best care for victims of drug and alcohol ... services to those plagued by substance use disorders in ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... March 30, 2015 Dr. Daniel Shapiro, one ... AZ, was recently featured on Phoenix’s Channel 12 News about ... is a minimally invasive alternative to facelifts developed by Dr. ... his team at Shapiro Aesthetic Plastic Surgery and Skin Klinic ... this exclusive news story on GenXLift. The story detailed the ...
Breaking Medicine News(10 mins):Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Dr. Daniel Shapiro Unveils New Minimally Invasive Facelift Procedure on Local Newscast 2
... 4 The Ensign Group, Inc.,(Nasdaq: ENSG ... skilled nursing,rehabilitative care services and assisted living companies, announced ... Alta, an 85-bed skilled,nursing facility in Salt Lake City, ... Center. , (Logo: ...
... Ind., Dec. 4 The holidays can become,stressful for many ... demand for time from friends, relatives and co-workers, and, this,year, ... of stress, many,people may look to give the gift of ... tree. , "Before giving ...
... Bogoch of Oncolab, Inc. have found that the concentration of replikins, ... to the mortality rate in human cancer of different cell types. ... quantitatively related to mortality rate. , ... Boston, MA ...
... In the midst of a season,of renewed focus ... States,healthcare providers from across the country are convening ... Wash., for the first U.S.,Public Sector Healthcare Provider ... technology (IT) innovations to solve real-world,problems in their ...
... are done having children feel responsible for the stored, ... than half are against implanting the embryos in anyone ... Duke University Medical Center. , "This really ... Drapkin Lyerly, MD, an obstetrician/gynecologist and bioethicist at Duke, ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... adult stem cells, said today that the call in ... discuss its announcement,regarding a management transition at the Company ... , The conference ...
Cached Medicine News:Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:A Season of Responsibility for New Pet Owners 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 2Health News:Cancer Mortality Increases With Cancer Cell Replikin Count 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 2Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 3Health News:Microsoft, Penn State Hershey Medical Center Showcase Road Map to Patient Flow Efficiencies at First Healthcare Provider Symposium 4Health News:Largest study of fertility patients shows concerns about embryo disposition 2Health News:Largest study of fertility patients shows concerns about embryo disposition 3Health News:ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of Inorganic Phosphorous in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
Medicine Products: